We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
AstraZeneca's (AZN) Tagrisso Hits Phase III Primary Endpoint
Read MoreHide Full Article
AstraZeneca plc (AZN - Free Report) announced that its lung cancer drug, Tagrisso, met the primary endpoint in a randomized phase III study (AURA3). The study evaluated the efficacy and safety of Tagrisso as a second-line treatment of patients suffering from EGFR T790M mutation-positive, locally-advanced or metastatic non-small cell lung cancer (NSCLC), whose disease had progressed following first-line EGFR tyrosine kinase inhibitor therapy.
Results showed that Tagrisso demonstrated superior progression-free survival (PFS) compared to standard platinum-based doublet chemotherapy with a safety profile that was found to be consistent with previous studies. In addition to PFS, the objective response rate, disease control rate and duration of response also achieved clinically meaningful improvement versus chemotherapy.
Meanwhile, full evaluation of AURA3 study data including an analysis of overall survival is currently ongoing and the company intends to present the data at an upcoming medical meeting.
We are encouraged by the phase III study results. We note that Tagrisso is currently approved in both the U.S. and EU for the treatment of patients with EGFR T790M mutation-positive advanced NSCLC. It is the first drug to be approved for this indication. Eligibility for treatment with Tagrisso is dependent on confirmation that the EGFR T790M mutation is present in the tumor.
Initial sales of the drug have been encouraging reflecting increased testing rates, which have been driving the number of new-patient starts.
Currently, Tagrisso is also being evaluated in the adjuvant and metastatic first-line settings, including patients with and without brain metastases, in leptomeningeal disease, and in combination with other treatments.
AstraZeneca is working on strengthening its oncology product portfolio and has several candidates in its pipeline. The company’s target is to launch at least six new medicines between 2014 and 2020.
AstraZeneca is a Zacks Rank #3 (Hold) stock. Some better-ranked stocks in the health care sector include Bristol-Myers Squibb Company (BMY - Free Report) , Innoviva, Inc. (INVA - Free Report) and Fibrocell Science, Inc. . All three stocks sport a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
AstraZeneca's (AZN) Tagrisso Hits Phase III Primary Endpoint
AstraZeneca plc (AZN - Free Report) announced that its lung cancer drug, Tagrisso, met the primary endpoint in a randomized phase III study (AURA3). The study evaluated the efficacy and safety of Tagrisso as a second-line treatment of patients suffering from EGFR T790M mutation-positive, locally-advanced or metastatic non-small cell lung cancer (NSCLC), whose disease had progressed following first-line EGFR tyrosine kinase inhibitor therapy.
Results showed that Tagrisso demonstrated superior progression-free survival (PFS) compared to standard platinum-based doublet chemotherapy with a safety profile that was found to be consistent with previous studies. In addition to PFS, the objective response rate, disease control rate and duration of response also achieved clinically meaningful improvement versus chemotherapy.
Meanwhile, full evaluation of AURA3 study data including an analysis of overall survival is currently ongoing and the company intends to present the data at an upcoming medical meeting.
ASTRAZENECA PLC Price
ASTRAZENECA PLC Price | ASTRAZENECA PLC Quote
We are encouraged by the phase III study results. We note that Tagrisso is currently approved in both the U.S. and EU for the treatment of patients with EGFR T790M mutation-positive advanced NSCLC. It is the first drug to be approved for this indication. Eligibility for treatment with Tagrisso is dependent on confirmation that the EGFR T790M mutation is present in the tumor.
Initial sales of the drug have been encouraging reflecting increased testing rates, which have been driving the number of new-patient starts.
Currently, Tagrisso is also being evaluated in the adjuvant and metastatic first-line settings, including patients with and without brain metastases, in leptomeningeal disease, and in combination with other treatments.
AstraZeneca is working on strengthening its oncology product portfolio and has several candidates in its pipeline. The company’s target is to launch at least six new medicines between 2014 and 2020.
AstraZeneca is a Zacks Rank #3 (Hold) stock. Some better-ranked stocks in the health care sector include Bristol-Myers Squibb Company (BMY - Free Report) , Innoviva, Inc. (INVA - Free Report) and Fibrocell Science, Inc. . All three stocks sport a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>